Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd.

Evogene Stock Down 0.7 %

NASDAQ:EVGN opened at $1.43 on Wednesday. Evogene has a 12-month low of $1.40 and a 12-month high of $10.40. The firm has a market capitalization of $7.68 million, a PE ratio of -0.32 and a beta of 1.36. The firm has a 50-day moving average price of $2.15 and a 200 day moving average price of $4.07.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.